REFCAR

Reference table for FDA-approved CAR T-cell products

CAR-T product Disease Study Publication ORR CR Median DOR 1-year PFS CRS G3+ CRS ICANS G3+ ICANS Median FU Comments
YESCARTA® 3L+ Large B cell lymphoma ZUMA-1 Locke et al, The Lancet Oncology, 2019 83% 58% 11m 70% 93%* 11% 64%* 32% 27m *from prior report in NEJM Neelapu et al 2017
YESCARTA® 3L+ Indolent (FL, MZL) ZUMA-5 Jacobson et al, The Lancet, 2021 96% 74% 11m 50% 82% 7% 59% 19% 19m
YESCARTA® 2L Large B cell lymphoma ZUMA-7 Locke et al, NEJM, 2022 83% (CAR) vs 50% (SOC) 65% (CAR) vs 32% (SOC) Not reported ~55% (CAR) vs ~30% (SOC) 92% 6% 60% 21% 25m Toxicity outcomes in CAR arm only
BREYANZI® 3L+ Large B cell lymphoma TRANSCEND NHL Abramson et al, The Lancet, 2020 73% 53% Not reached 40% 42% 2% 30% 10%
BREYANZI® 2L Large B cell lymphoma TRANSFORM Kamdar et al, The Lancet, 2020 86% (CAR) vs 48% (SOC) 66% (CAR) vs 39% (SOC) Not reached (CAR) vs 14.5m (SOC) - in CR pts 53% (CAR) vs 34% (SOC) 49% 1% 12% 4% 6m Toxicity outcomes in CAR arm only
TECARTUS® R/R Mantle cell lymphoma ZUMA-2 Wang et al, NEJM, 2020 93% 67% Not reached 40% 91% 15% 63% 31%
TECARTUS® R/R B-ALL ZUMA-3 Shah et al, The Lancet 71% 13m ~50% 89% 24% 60% 25% 16m *allo-HCT post CAR-T in 18%
KYMRIAH® 3L+ Large B cell lymphoma JULIET Schuster et al NEJM, 2019 52% 40% Not reached ~40% 58% 22%* 21% 12% 28m *Per PENN scale
KYMRIAH® 3L+ Follicular lymphoma ELARA Fowler et al. Nat Med, 2022 86% 69% Not reached 67% 49% 0% 37% 3% CRS per Lee scale, ICANS per CTCAE
ABECMA® 4L+ Multiple myeloma KarMMa Munshi et al, NEJM, 2021 73% 33% 11m* ~40% 84% 5% 18% 3% *per 5/19/21 BMS press release
CARVYKTI® 4L+ Multiple myeloma CARTITUDE-1 Berdeja et al, NEJM 2021 97% 67% Not reached 77% 95% 4% 21% 9% 12m

~ estimated from the Kaplan-Meier curves (not directly reported in the publication)